A study published in 2024 across multiple cancer centers concerning mCRPC treated with [177Lu]Lu-PSMA-617 radioligand reported favorable clinical responses in over 160 patients, with more than 50% demonstrating a significant PSA response; side effects included anemia and thrombocytopenia [48]. The gene discussed is FOLH1; the disease is cancer.